Cipla gets approval to sell Truvada drug in India from DCGI

24 May 2016 Evaluate

Cipla has received regulatory approval in India from the Drug Controller General of India (DCGI) to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Truvada is priced at Rs 2,200 for a month. The Truvada has been in use in India for about eight years now, but only for the treatment of people with the HIV infection. The big difference now is that it is used to prevent infection in healthy people.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1379.85 -18.10 (-1.29%)
19-Jan-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.30
Dr. Reddys Lab 1167.10
Cipla 1379.85
Zydus Lifesciences 864.60
Lupin 2175.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×